Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Ceragenix is developing next generation prescription therapies based on its platform of surface active technologies – skin Barrier Repair Technology (BRT) and a new class of anti-infectives called CerageninsÔ. Our goal is to become a market leader in developing novel and high-impact therapies and medical products for selected markets in infectious disease and dermatology. The Company seeks to enjoy early revenue opportunities from its first and recently FDA-approved skin Barrier Repair Therapy product EpiCeram® and will use this cash flow to focus on development of Ceragenin product candidates for the larger anti-infectives market in which there continues to be a significant need for novel antibiotics with low potential for ( www.ceragenix.com )
Ceragenix Pharmaceuticals , Inc.
1444 Wazee Street Suite 210
Denver, Colorado 80202
USA
Tel: (720) 946-6440
Fax: (303) 534-1800